Resverlogix Corp. (RVX : TSX)
Common Stock
$0.10
CAD
+0.01 (5.26%)
Last updated: 2026-06-02
RVX
Resverlogix Corp.
WealthAwesomePerformance
1 Day
+5.26%
1 Week
+5.26%
1 Month
+0.00%
YTD
+0.00%
Key Statistics
Market Cap
$31.70M
52W High
$0.30
52W Low
$0.04
P/E Ratio
-
50 Day MA
$0.10
200 Day MA
$0.11
Beta
1.04
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/2/2026 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | 14,500 |
| 6/1/2026 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | 55,550 |
| 5/29/2026 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | 4,500 |
| 5/28/2026 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | 60,700 |
| 5/27/2026 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | 301,854 |
| 5/26/2026 | $0.09 | $0.10 | $0.09 | $0.10 | $0.10 | 141,018 |
| 5/25/2026 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | 11,971 |
| 5/22/2026 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | 33,700 |
| 5/21/2026 | $0.10 | $0.10 | $0.09 | $0.10 | $0.10 | 47,210 |
| 5/20/2026 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | 8,500 |
Analyst Price Targets
Based on analyst covering RVX
Wall Street analysts forecast RVX stock price to rise 7600.0% over the next 12 months.
Consensus
No RatingAvg. Target
C$7.70
+7600.0% Upside
Current Price
C$0.10
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RVX's historical volatility
30-Day Vol
64.2%
Annualized
90-Day Vol
90.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.08
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.09 | C$0.08 โ C$0.12 |
| 60 trading days | C$0.09 | C$0.06 โ C$0.12 |
| 90 trading days | C$0.08 | C$0.06 โ C$0.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-4.55M
- Profit Margin
- 0.00%
- ROE (TTM)
- 0.00%
- EPS (Diluted)
- -0.04
- Book Value
- -0.43
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About RVX
Articles Featuring RVX.TO
Latest articles and analysis covering RVX.TO
